Press release
New Report Examines the Febrile Neutropenia Market Research
The market of febrile neutropenia is majorly driven by the efforts of key players to develop novel and cost effective therapeutics. For example, in July 2014, Taiho Pharmaceutical Co., Ltd. filled an application for approval of ZOSYN 2.25 and ZOSYN 4.5 (generic name- tazobactam piperacillin) for additional indication of febrile neutropenia. This product is a combination of antibacterial β-lactamase inhibitor and can be used intravenously. Moreover, in April 2014, Amgen, Inc. collaborated with ONS Edge, Inc. to help educate nurses regarding the patients who are at the risk of febrile neutropenia.
Obtain Report Details @ https://www.transparencymarketresearch.com/febrile-neutropenia-market.html
Thus, these types of efforts will build healthy platform to develop the market of febrile neutropenia hence stimulates the market growth. Additionally, large number of therapeutics under clinical pipelines by key companies will further stimulate the market growth in near future. Positive initiatives by North American and European governments will further drive the market growth of febrile neutropenia.
For example, in September 2013, U.S. Food Drug and Administration (U.S. FDA) approved phase III study of Neulasta (pegfilgrastim) by Amgen, Inc. This study demonstrates increase of white blood cells in patients who are undergoing myelo-suppressive chemotherapy. In addition, in June 2010, Nivestim (TM), a new biosimilar filgrastim by Hospira, Inc. is approved by European Commission. This drug is mainly used for the prevention of febrile neutropenia and offers cost-effective treatment option for neutropenia.
However, lack of specific treatment that enables to treat all the symptoms of this disorder may restrain the growth of this market. In addition, high generic competition among the key players leads to price erosion and ultimately restrains the overall growth of febrile neutropenia market.
Geographically, North America dominates the global febrile neutropenia market. High degree of therapeutic needs for febrile neutropenia coupled with presence of large number of key players like Amgen, Inc., Aequus BioPharma, Inc. and others in North American market will drive the growth of the market. Europe is considered as the second largest market of febrile neutropenia. Large pool of patients under the diagnosis of this disease coupled with increasing demand of treatment fuels the growth of febrile neutropenia market.
In addition, Asia-Pacific region is considered as an emerging market for febrile neutropenia due to the launch of novel drugs with improved efficacy by key companies. In addition, growing awareness for this disorder among the people will further stimulate the growth of febrile neutropenia market in Asia-Pacific region.
Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2857
Some of the key players in the febrile neutropenia market include Xenetic Biosciences plc, Richter Gedeon Nyrt., Amgen, Inc., Hospira, Inc., Eli Lilly and Company, USV Limited, Aequus BioPharma, Inc., Taiho Pharmaceutical Co., Ltd. and others.
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release New Report Examines the Febrile Neutropenia Market Research here
News-ID: 888309 • Views: …
More Releases from Transparency Market Research
Global Embolotherapy Market Set to Reach USD 7.2 Billion by 2035, Driven by Inno …
The global embolotherapy market is poised for substantial growth over the next decade, with the market size projected to surge from US$ 3.5 billion in 2024 to US$ 7.2 billion by 2035, expanding at a CAGR of 6.7% from 2025 to 2035, according to the latest market research. This growth trajectory is propelled by the increasing incidence of cancer and vascular diseases, a rising preference for minimally invasive procedures, and…
DC Fast Charging Station Market Expanding at 36.3% CAGR Through 2035 - By Compon …
The global DC Fast Charging Station Market was valued at US$ 4.6 Bn in 2024 and is projected to reach US$ 121.5 Bn by 2035, expanding at a robust compound annual growth rate (CAGR) of 36.3% from 2025 to 2035. This exponential growth trajectory underscores the pivotal role of high-power DC charging infrastructure in enabling mass electric vehicle (EV) adoption worldwide.
Access key findings and insights from our Report in this…
Blood-based Biomarker for Alzheimer's Disease Market Outlook 2035: Rising from U …
The global blood-based biomarker for Alzheimer's disease market is undergoing a transformative phase as healthcare systems shift toward earlier, less invasive, and more scalable diagnostic approaches for neurodegenerative disorders. Valued at US$ 127.4 million in 2024, the market is projected to expand rapidly and reach US$ 554.2 million by 2035, registering a strong compound annual growth rate (CAGR) of 14.3% from 2025 to 2035. This growth reflects the urgent global…
Flexible Battery Technology Market Set for Rapid Growth to USD 552.6 Million by …
The Flexible, Printed, and Thin Film Batteries Market is gaining strong momentum as industries move toward lightweight, compact, and form-factor-driven electronic designs. Traditional rigid batteries are no longer sufficient for modern applications such as wearable electronics, smart medical devices, IoT sensors, and flexible displays. These next-generation batteries provide ultra-thin profiles, bendability, and seamless integration into electronic substrates, enabling entirely new product categories.
The Flexible, Printed, and Thin Film Batteries Market is…
More Releases for Febrile
Febrile Seizures Market Business Growth and Industry Development by 2034
The Febrile Seizures Market Is Set To Grow At An Estimated CAGR Of 6.2% From 2025 To 2034, Rising From $3.2 Billion In 2024 To $5.6 Billion By 2034.
On April 10, 2025, Exactitude Consultancy., Ltd. released a research report titled "Febrile Seizures Market" This report offers a new perspective on the Febrile Seizures Market covering an extensive range of aspects including market overview, expenditure analysis, import trends, segmentation, key players,…
Febrile Seizures Market: Global Industry Analysis and Forecast (2024-2030)
Febrile Seizures Market to reach USD 1573.16 Mn at a CAGR of 4.5 percent over the forecast period
The Febrile Seizures Market was valued at USD 1156 Million in 2023, with revenue expected to grow at a CAGR of 4.5%, reaching nearly USD 1573.16 Million by 2030.
To access more details regarding this research, visit the following webpage:https://www.stellarmr.com/report/Febrile-Seizures-Market/2064
Febrile Seizures Market Scope and Research Methodology
The Febrile Seizures Market report employs an extensive research…
Febrile Seizures Market Anticipates Growth in Forecast Period 2024-2031
The "Febrile Seizures Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats, alongside…
Acute Febrile Neutrophilic Dermatosis Market - Defending Skin Integrity with Adv …
Newark, New Castle, USA - new report, titled Acute Febrile Neutrophilic Dermatosis Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Acute Febrile Neutrophilic Dermatosis market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Acute Febrile Neutrophilic Dermatosis market. The report offers…
Acute Febrile Neutrophilic Dermatosis Market Insights, Forecast to 2031
Acute Febrile Neutrophilic Dermatosis Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Acute Febrile Neutrophilic Dermatosis industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It…
Febrile Neutropenia Market Significantly Stepping towards the Success Till 2027
Alpha-2 antiplasmin, commonly known as a plasmin inhibitor, is a glycoprotein made by the liver, kidneys, and other bodily organs. Alpha-2 Antiplasmin is a serine protease inhibitor belonging to the Serpin superfamily that is responsible for the breakdown of fibrin clots and the inhibition of fibrinolysis. Due to an increase in fibrinolysis, a lack of Alpha 2 antiplasmin causes bleeding problems. Internal bleeding is caused by a congenital lack of…
